93 related articles for article (PubMed ID: 9322892)
1. Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leukemic blasts.
Dalal BI; Wu V; Barnett MJ; Horsman DE; Spinelli JJ; Naiman SC; Shepherd JD; Nantel SH; Reece DE; Sutherland HJ; Klingemann HG; Phillips GL
Leuk Lymphoma; 1997 Jul; 26(3-4):299-306. PubMed ID: 9322892
[TBL] [Abstract][Full Text] [Related]
2. [Proportion of CD34(+)CD38(-) cell population in bone marrow of patients with de novo AML as prognostic factor of complete remission at first course of induction chemotherapy].
Zhang CP; Wei H; Wang HJ; Huai L; He K; Chen YR; Lin D; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1268-72. PubMed ID: 22040986
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of myeloperoxidase containing blast cells in acute myelogenous leukaemia.
Advani SH; Hegde UP; Iyer RS; Gopal R; Saikia TK; Pai SK; Nair CN; Kurkure PA; Pai VR; Nadkarni KS
Indian J Med Res; 1993 Feb; 98():8-14. PubMed ID: 8388366
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometry-based assessment of mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.
Kim HP; Bernard L; Berkowitz J; Nitta J; Hogge DE
Cytometry B Clin Cytom; 2012 Sep; 82(5):283-94. PubMed ID: 22508650
[TBL] [Abstract][Full Text] [Related]
5. Behenoyl cytosine arabinoside, daunorubicin, 6-mercaptopurine, and prednisolone combination therapy for acute myelogenous leukemia in adults and prognostic factors related to remission duration and survival length.
Ohno R; Kato Y; Nagura E; Murase T; Okumura M; Yamada H; Ogura M; Minami S; Suzuki H; Morishima Y
J Clin Oncol; 1986 Dec; 4(12):1740-7. PubMed ID: 3465875
[TBL] [Abstract][Full Text] [Related]
6. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
[TBL] [Abstract][Full Text] [Related]
8. Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML.
Sperling C; Büchner T; Creutzig U; Ritter J; Harbott J; Fonatsch C; Sauerland C; Mielcarek M; Maschmeyer G; Löffler H
Leuk Lymphoma; 1995 May; 17(5-6):417-26. PubMed ID: 7549832
[TBL] [Abstract][Full Text] [Related]
9. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
10. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate.
Lauria F; Raspadori D; Rondelli D; Ventura MA; Fiacchini M; Visani G; Forconi F; Tura S
Leukemia; 1997 Dec; 11(12):2075-8. PubMed ID: 9447823
[TBL] [Abstract][Full Text] [Related]
11. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML).
Wang L; Gao L; Xu S; Gong S; Liu M; Qiu H; Xu X; Ni X; Chen L; Lu S; Chen J; Song X; Zhang W; Yang J; Hu X; Wang J
Ann Hematol; 2014 Oct; 93(10):1685-94. PubMed ID: 24844781
[TBL] [Abstract][Full Text] [Related]
12. AC133 antigen as a prognostic factor in acute leukemia.
Lee ST; Jang JH; Min YH; Hahn JS; Ko YW
Leuk Res; 2001 Sep; 25(9):757-67. PubMed ID: 11489469
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic factor analysis of 77 old patients with acute myelogenous leukemia].
Shao B; Gao YR; Wang C; Yan SK; Cai Q; Jiang JL; Yang J; Bai HT; Zhao M; Zhao CX
Ai Zheng; 2006 Aug; 25(8):1007-12. PubMed ID: 16965684
[TBL] [Abstract][Full Text] [Related]
14. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression.
Shi P; Zha J; Guo X; Chen F; Fan Z; Huang F; Meng F; Liu X; Feng R; Xu B
Pharmacogenomics; 2013 Jan; 14(1):17-23. PubMed ID: 23252945
[TBL] [Abstract][Full Text] [Related]
15. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
16. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
[TBL] [Abstract][Full Text] [Related]
17. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10).
Geller RB; Zahurak M; Hurwitz CA; Burke PJ; Karp JE; Piantadosi S; Civin CI
Br J Haematol; 1990 Nov; 76(3):340-7. PubMed ID: 1702006
[TBL] [Abstract][Full Text] [Related]
18. CD34 expression in native human acute myelogenous leukemia blasts: differences in CD34 membrane molecule expression are associated with different gene expression profiles.
Oyan AM; Bø TH; Jonassen I; Ulvestad E; Gjertsen BT; Kalland KH; Bruserud O
Cytometry B Clin Cytom; 2005 Mar; 64(1):18-27. PubMed ID: 15668952
[TBL] [Abstract][Full Text] [Related]
19. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia.
Fruchart C; Lenormand B; Bastard C; Boulet D; Lesesve JF; Callat MP; Stamatoullas A; Monconduit M; Tilly H
Am J Hematol; 1996 Nov; 53(3):175-80. PubMed ID: 8895688
[TBL] [Abstract][Full Text] [Related]
20. Therapy of acute myelogenous leukemia: results of combination chemotherapy with cytarabine, daunorubicin and 6-mercaptopurine.
Ko WS; Chen LM; Hwang SH; Chao TY; Wang CC; Kao WY; Lee WC; Hwang WS
Zhonghua Yi Xue Za Zhi (Taipei); 1991 Sep; 48(3):185-9. PubMed ID: 1657335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
